PEER REVIEW HISTORY

BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. Some articles will have been accepted based in part or entirely on reviews undertaken for other BMJ Group journals. These will be reproduced where possible.

ARTICLE DETAILS

TITLE (PROVISIONAL)	Male Pattern Baldness and Its Association with Coronary Heart
	Disease: A Meta-Analysis
AUTHORS	Yamada, Tomohide; Hara, Kazuo; Umematsu, Hitomi; Kadowaki,
	Takashi

VERSION 1 - REVIEW

REVIEWER	Paulo A Lotufo University of Sao Paulo
REVIEW RETURNED	12-Jan-2013

GENERAL COMMENTS	No major corrections for a well presented systematic review.

REVIEWER	Dr Stephen-Mark Cooper (PhD)
	Reader & Graduate Studies Coordinator Cardiff School of Sport : Athrofa Prifysgol Cymru, Caerdydd Cardiff Metropolitan University : Prifysgol Fetropolitan Caerdydd
	There are no competing interests.
REVIEW RETURNED	15-Jan-2013

The authors need to consider the points about the table and figures I
have raised in my review of the MS attached herewith.
In this manuscript (MS), the authors have applied some of the most
appropriate meta-analysis statistical methods to investigate the
relationship between male pattern baldness and coronary heart
disease (CHD) risk factors.
The study is conducted on a large comple of subjects but
The study is conducted on a large sample of subjects but
uniortunately these subjects are drawn from a total of only six
previously published studies.
As I am not an expert on the body of research that is the focus of
this meta-analysis I have limited myself to making general
comments about the MS and its presentation, and more specifically
the research design and the statistical analyses of the data. The
study is well-designed, the research is well-organised, the data
seem to have been collected appropriately and the data are
expertly handled and analysed. As far as the methodology is

concerned I am convinced that I could replicate the study based on the description the authors provide in the MS. The authors communicate their arguments in a clear and concise manner in a paper that is well crafted and skilfully written.

If I have any criticisms of the MS at all it is to do with the lack of consistency in the expression of terms; primarily the mixedeconomy use of relation/relationship/association throughout when identifying the aim of the meta-analysis. 'Relation' is a term that should not be used at all but 'relationship' is acceptable as is 'association' but not the mix of terms that appears here. The authors should chose one term and be consistent with its use throughout the MS. If it is of any help, 'relationship' unusually is linked with a correlation based analysis and 'association' when a chi-squared based test has been applied. Interestingly, the authors indicate in the method section that Cochrane's χ^2 test was used to analyse data but no feedback on outcomes are recorded in the results or the discussion sections of this MS. I also found the amount of information, and the manner in which it was being expressed in the Table and in the Figures confusing. I would also like to see all statistical indices expressed in italics where appropriate (e.g. CI, P, n, χ^2 , l^2 etc.).

I realise that such points might seem pedantic but then ... one man's pedantry is another man's precision! Seriously, this was a really good paper, and even though I have no background in the academic area other than the research design and the statistics used, it was one which I thoroughly enjoyed reading.

My specific comments are as follows.

Abstract (page 2)

Line 12: ... so are the authors confirming 'the association' or 'the relationship' between (not of) male pattern baldness and (not with) coronary heart disease (CHD)? I'm asking for a consistent term to be used throughout the MS not the mixed-economy of terms used here.

Line 26: ... suggest ... both 'baldness' and 'coronary heart disease' and the reference lists of those studies identified were also searched.

Line 44: ... suggest ... interval (95% CI) were estimated using the ...

Line 53: suggest Included 850 possible studies, three cohort studies and three case-control studies (36,990 subjects).
Page 3; Line 9: (and elsewhere in the MS) 95% <i>Cl</i> : 1.08 – 1.63, <i>P</i> = 0.008, l^2 = 25%) (spacing, superscripting and italics)
Line 15: the same thing (95% <i>Cl</i> : 1.11 – 1.86, $P = 0.006$, $l^2 = 0$ %).
Line 38: (and elsewhere in the MS)
Line 40: (and throughout the MS) might (not may)
Article summary (page 4)
Line 12: Again is it 'the association' or 'the relationship' between (not of) male pattern baldness (androgenetic alopecia) and (not with) coronary heart disease (CHD)? A consistent use of term.
Line 21: suggest studies with a total of 36,690 subjects the relationship depends upon the
Line 29: might (not may)
Line 35: suggest investigated in further studies
Line 44: do you mean relationship or association? Not 'relation'.
Line 50: spacing 11.0 – 14.0 years.
Line 53: might (not may)
Introduction (page 5)
Line 18: suggest participants in wellbeing programmes often also
Line 21: suggest screening has yet to be confirmed. Young <i>et al.</i> (2009) reported that
Line 27: suggest scintigraphy (3), and McEvoy <i>et al.</i> (2011) also reported that computed tomography screening You don't use CT again so it should not be abbreviated here – I'm presuming it is computed tomography of course!
Line 50: suggest is a classic feature of this thinning condition (7).
Line 53: suggest with the risk of CHD (8-13).
Line 58: Is it 'the relationship' (or 'the association') between

baldness and CHD? Not 'relation'.
Page 6; line 6: or is it the relationship'?! Also, you could provide some examples here from the literature to illustrate how the associations/relationships vary.
Line 15: suggest a cardiac event thereby allowing the delivery
Methods (page 6)
Line 35: you are very precise about the end of the data collection (27/11/2012) but from when in 1950 did you start the data collection?
Line 38: suggest headings " b aldness" (and " c oronary heart Also, did you put CHD into the search as well as coronary heart disease?
Line 44: suggest observational studies that estimated the association or is it 'relationship'?
Line 47: suggest The reference lists of all studies identified were also reviewed.
Page 7; line 6: involved a full-text review.
Line 9: association or relationship but not relation.
Line 15: covariates not confounders.
Line 56: non-randomized.
Page 8; line 6: (15)? Should be on previous page.
Line 27: is this the country where the study was conducted or where the article was published?
Line 38: covariates not confounders.
Line 41: (and elsewhere in the MS) you used (95% <i>CI)</i> previously be consistent. Also, you could do with a reference for the DerSimonian-Laird random effect model here.
Line 47: (and elsewhere in the MS) <i>z</i> -statistic test. Cochrane's χ^2 test and the f^2 test a threshold <i>P</i> -value of 0.10 (italics). Also, why was the <i>P</i> -value of 0.10 chosen – it can't be arbitrary – what type of error were you willing to make?
Page 9; line 6: you need a reference here for the Begg and Egger test. But is it not Begg's test and Egger's test (this is suggested on p.13, line 44)? In which case you need a reference for each.

Results (page 9)
Line 44: suggest used for the present meta-analysis.
Line 53: The six studies that were selected included three cohort studies and three case-control
Page 10; line 6: is this the country where the study was conducted or where the article was published?
Line 9: suggest the other two (8, 12) were conducted in the
Line 12: they are samples in studies not populations. Also, which study (ref) had the 1437 subjects and which study (ref) had the sample of 19112 subjects?
Line 15: suggest In five of the six studies
Line 21: suggest employed in four studies being used in the other two studies
Line 30: suggest original scale to the following five categories:
Line 47: suggest scales, Ford <i>et al</i> . (1996) classified
Line 55: suggest In the other study, Miric et al. (1998)
Page 11; line 18: suggest on all three cross-sectional
Line 24:suggest influence of covariates. The reports on all three studies
Line 29:suggest but the other five studies
Line 35: association or relationship?
Line 41:suggest studies used in the present meta-analysis
Line 53:suggest Among the six studies
Page 12; line 123:suggest In the three cohort
Line 15: (and throughout the rest of the MS) it should be l^2 throughout.
Line 21: association or relationship?
Line 27: suggest In the three case-control
Line 35: suggest was non-significant

Line 50: association or relationship?
Page 13; line 12: suggest there was a non- significant (association or relationship)
Line 21: suggest baldness into four grades
Lines 23 & 47: association or relationship?
Line 50: suggest revealed non- significant $P \ge 0.05$. Italics and spacing.
Discussion (page 14)
Line 9: suggest The present meta-analysis of six studies
Line 12: suggest was significantly associated (or related) with
Line 15: suggest was non-significantly associated (or related) with
Line 21: suggest the relationship between CHD and baldness was
Line 32: is it Regaine?
Line 41: suggest This might lead to the shedding
Page 15; line 18: association or relationship?
Line 56: suggest baldness might be caused
Page 16; line 24: suggest Strengths and limitations
Line 26: suggest The strengths of the present meta-analysis
Line 38: suggest However, the present meta-analysis
Line 47: suggest factors showed non-significant
Line 55: suggest contributed to the heterogeneity
Page 17; line 6: suggest Lesko et al. (1993)
Line 15: suggest Lesko <i>et al</i> . (1993)
Lines 21 & 22: why does the font change here?
Line 27: already (spelling)
Line 27: according to the reference list the Rebora article only has the one author so et al. is not needed but the date needs to be

appended by Rebora (2001, 33), Lotufo <i>et al.</i> (2000, 10)
Line 35: association or relationship?
Line 44: might not may
Conclusions (page 18)
Line 22, suggest baldness was significantly appearing (or
related?) with
Line 26: suggest and the relationship (or association) was
dependent
Line 29: association or relationship?
Line 33: suggest than with frontal
Line 41: association or relationship? Also, suggest
investigated in further
Table 1 (page 27)
This is certainly a 'busy' table but it is necessary in the context of the
research design and the analysis. In the legend decide if it is an
association or a 'relationship'. In the column titles is it the 'year' of publication that is meant? What does 'country' relate to – where the
study was conducted or where the article was published? Do you
mean the <i>n</i> of subjects ?
Figure 1 (page 29)
On the copy I downloaded for review this Figure was overtyped with
stabndard BMJ information.
Figures 2, 3 & 4 (pages 30, 31 & 32)
These were confusing figures. It was not clear what was trying to be

illustrated here. The numerics were fine but I was unsure what the schematics were meant to portray. f^2 not I squared.

REVIEWER	Shih-Ying Lee. MD
	Director in Department of Neurology, West Garden Hospital, Taiwan.
REVIEW RETURNED	25-Jan-2013

GENERAL COMMENTS	There are several points need to be clarified as listed in the followings:
	1. There were several occasions in this paper mentioned of younger
	(Check Page 3, line 9-12; page 12, line 18 & $36-39$). They might
	need an explanation or to be more consistent on the range of age.
	1.32, P=0.28).
	3.Page 5, line 52-55: Since the result of ref.13 did not support
	should be (8-12) instead of (8-13). (check page 11, line 30); Also,
	page 12, line 48-51: "All three studies (10,11,13)" needs to be rephrased.
	4.Page 16, line 18: By "arteriosclerosis", did you mean atheroscierosis?
	5. There are several articles emphasized on early onset androgenetic alopecia like ref. 22, 25, 28 of this article, and "Early onset of
	androgenetic alopecia (AGA) associated with early severe coronary
	VA, et al. J of cardiovascular Risk, 2001, Vol; 8(3): 147-151.". It
	would be nice to add some concept of early onset AGA to the risk of
	UHD in the discussion and in the weakness of this article.

VERSION 1 – AUTHOR RESPONSE

1.'Impact of' in the title seems to conflict with the study aim which to assess the 'association', not 'impact'. '

Thank you for your numerous valuable comments about our paper. The title has been changed as follows in response to your advice: "Male Pattern Baldness and Its Association with Coronary Heart Disease: A Meta-Analysis".

2. A limitation is that you only looked at English language studies;

We only searched English studies for inclusion in this meta-analysis and we might possibly have overlooked some non-English literature, which might have resulted in a selection bias. However, we also investigated all of the references in each study as far as possible. Also, there was no significant publication bias, and the fact was added to the Discussion. Page 17/Lines 9-24.

3. We would also think you should provide a more balanced message in you conclusion. At present you say younger men with vertex baldness should be encouraged to increase their cvd profile, but we think this needs to be balanced against the potential for over-medicalising - after all male pattern baldness affects 30-40% of adult men.

The sentence starting with "Thus, cardiovascular risk factors~" in Conclusions was toned down to

"Thus, cardiovascular risk factors should be reviewed carefully in men with vertex baldness, especially younger men, and they probably should be encouraged to improve their cardiovascular risk profile". The following sentence was also added: "However, the usefulness of CHD screening in asymptomatic populations is yet to be elucidated, so the screening method (e.g., exercise ECG, coronary computed tomography, or scintigraphy) employed should be practicable in terms of its advantages/disadvantages and cost performance, and patients should be evaluated for eligibility before screening to avoid possible over- medicalization since male pattern baldness affects 30-40% of adult men (5)". Page 19/Lines 9-29.

Dear Dr. Lotufo,

1. No major corrections for a well presented systematic review.

Thank you for reviewing our manuscript and we appreciate your kind comments.

Dear Dr. Cooper

Thank you for your valuable advice. We were deeply impressed by your encouragement. We are convinced that our report has been improved thanks to your detailed and accurate comments. We have revised the text based on a total of 85 specific comments. Replies to other questions are shown below.

1. If I have any criticisms of the MS at all it is to do with the lack of consistency in the expression of terms; primarily the mixed-economy use of relation/relationship/association throughout when identifying the aim of the meta-analysis.

In response to the advice of Dr. Richard Sands, the managing editor, and Dr Alison Walker, Associate editor, the title of the study was changed to "Male Pattern Baldness and Its Association with Coronary Heart Disease: A Meta-Analysis". The term "association" has now been used throughout the text to maintain consistency with the title.

2. 'Interestingly, the authors indicate in the method section that Cochrane's χ 2 test was used to analyse data but no feedback on outcomes are recorded in the results or the discussion sections of this MS.

The results of Cochrane's test for heterogeneity have been added to the Results section. The figures were also corrected. Page 12/Lines 15-30.

3. I would also like to see all statistical indices expressed in italics where appropriate (e.g. CI, P, n, χ 2, I2 etc.).

"I squared" was changed to "I2" throughout the text.

4. Methods (page 6)Line 35: you are very precise about the end of the data collection (27/11/2012) but from when in 1950 did you start the data collection?

We started the data collection on January 1, 1950. This has been added to the "Methods" section. Page 6/Line 38.

5. Methods Line 38: ... suggest ... headings "baldness" (... and "coronary heart ... Also, did you put CHD into the search as well as coronary heart disease?

We did not put CHD into the search because it is an abbreviation and was not likely to be in the title of a paper or abstract. We searched again using CHD just for confirmation, but the number of papers

retrieved was nearly the same and did not affect the number of papers included in the present metaanalysis.

6. Methods Line 27: is this the country where the study was conducted or where the article was published?

The country where the study was conducted. This has been added to the "Methods" section. Page 8/Lines 29-32.

7. Methods Line 41: you could do with a reference for the DerSimonian-Laird random effect model here.

"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep; 7(3): 177-88." was added to the list of references (Ref #16). Page 8/Lines 49.

8. Methods Line 47: ... (and elsewhere in the MS) ... z-statistic test. Cochrane's χ^2 test and the I2 test a threshold P-value of 0.10 (italics). Also, why was the P-value of 0.10 chosen – it can't be arbitrary – what type of error were you willing to make?

A P value of <0.05 was also made significant for the test of heterogeneity and the text has been corrected accordingly. Page 9/Lines 15-18.

9. Methods Page 9; line 6: you need a reference here for the Begg and Egger test. But is it not Begg's test and Egger's test (this is suggested on p.13, line 44)? In which case you need a reference for each.

References to both the Begg test (Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec; 50 (4): 1088-101.) and the Egger test (Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13; 315 (7109): 629-34) have been added (Ref #18,19). Page 9/Line 9.

10. Results (page 9); Line 12: they are samples in studies not populations. Also, which study (ref) had the 1437 subjects and which study (ref) had the sample of 19112 subjects?

Lesko (Ref 11) had a sample size of 1,437 subjects and Lotufo (Ref 10) had a sample size of 19,112 subjects. This information has been added. Page 10/Lines 15-18.

11. Discussion (page 14); Line 32: is it Regaine?

Yes. The brand name of minoxidil is Regaine in Europe and Asia, but it is Rogaine in the U.S. and Canada. Both Rogaine/Regaine are listed now. Page 14/Line 52.

12. Figure 1 (page 29): On the copy I downloaded for review this Figure was overtyped with standard BMJ information.

As you pointed out, the PDF file for peerreview was overtyped with BMJ information. However, the original PowerPoint file doesn't include this information. I will check this during proofread process. Thank you.

13. Table 1 (page 27) This is certainly a 'busy' table but it is necessary in the context of the research design and the analysis. In the legend decide if it is an 'association' or a 'relationship'. In the column titles is it the 'year' of publication that is meant? What does 'country' relate to – where the study was conducted or where the article was published? Do you mean the n of 'subjects'?

"Year" means the year of publication and the "country" refers to the country where the study was conducted. "Subjects" mean all subjects who participated in the study and the text has been corrected accordingly. Page 8/Lines 29-32.

14. Figures 2, 3 & 4 (pages 30, 31 & 32)

These were confusing figures. It was not clear what was trying to be illustrated here. The numerics were fine but I was unsure what the schematics were meant to portray. I2 not I squared.

The statement "RR for presence of male pattern baldness" has been added to the RR section of the Forest Plot. Results of the test of heterogeneity have also been added. As instructed, "I squared" was changed to "I2".

Dear Dr. Lee Thank you for reviewing our manuscript and we appreciate your kind comments.

1. There were several occasions in this paper mentioned of younger men (55 or <=60 years), but in Fig.2&3, they used <=60 years (Check Page 3, line 9-12; page 12, line 18 & 36-39). They might need an explanation or to be more consistent on the range of age.

"Patients aged <=60 years" in Figs. 2 and 3 was corrected to "Patients aged <55 or <=60 years".

Page 3, line 27, at the end: (0.92-1.32. P=0.28) should be (0.92-1.32, P=0.28).
Page 5, line 52-55: Since the result of ref.13 did not support baldness associated with risk of coronary heart disease (CHD), it should be (8-12) instead of (8-13). (check page 11, line 30); Also, page 12, line 48-51: "All three studies (10,11,13)..." needs to be rephrased.

Corrections were made as instructed.

4. Page 16, line 18: By "arteriosclerosis", did you mean atheroscierosis?

This was corrected to "atherosclerosis".

5. There are several articles emphasized on early onset androgenetic alopecia like ref.22,25,28 of this article, and "Early onset of androgenetic alopecia (AGA) associated with early severe coronary heart disease: a population-based case control study. By Matilainen VA, et al. J of cardiovascular Risk, 2001, Vol; 8(3): 147-151.". It would be nice to add some concept of early onset AGA to the risk of CHD in the discussion and in the weakness of this article.

Thank you for this very useful advice. An addition was made to the Discussion as follows: "Our metaanalysis of young men alone also showed a significant relationship between androgenetic alopecia (AGA) and the risk of CHD like that revealed by the meta-analysis of men of all ages (Figs. 2,3). The results were consistent with those of many studies published so far, which have shown that early onset of AGA is related to a risk of early severe CHD and its risk factors (23,24,25,26)". The paper of Dr. Matilainen was also added (Ref #26).Page 14/Lines 35-44.